ReviewFuture medicinal chemistry2025
A comprehensive review on the latest advances of dimeric anticancer prodrugs.
Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advancement of targeted drug delivery systems has opened up a wide array of opportunities in cancer therapy, leading to the exploration of various strategies. Among these, the use of prodrugs stands out as a particularly promising approach in targeted cancer treatment, aimed at enhancing the selectivity and effectiveness of cytotoxic agents. In the last few years, there has been considerable progress in the area of dimeric-based prodrugs aimed at cancer therapy. The advantages presented by dimeric-based prodrugs have significantly improved the efficiency of delivering anticancer drugs, characterized by a high drug loading capacity, advantageous pharmacokinetics, and drug release that responds to tumor stimuli. With respect to the importance of drug dimerization in the field of prodrug development, herein we review the latest reports covering research in dimeric prodrugs. We have categorized the article according to the reported anticancer agents. We have also spent a great deal of attention on different types of used linkers and methods of the dissociation of dimeric prodrugs into free monomeric drugs. Readers will easily be able to compare between the reported research using the same drugs with different linkers or different dissociation methods as well as different cancer cell lines targeted in the studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.